Sentence examples for pd administration from inspiring English sources

Pax7 accumulation, also confirmed by western blotting, is largely prevented by PD administration (Fig. 5B).

The present work confirms that circulating IL-6 markedly increases in the C26 hosts, yet PD administration does not prevent this increase (Fig. S3).

A different pattern can be observed for Pax7, whose expression in both differentiating myoblasts (Fig. S5) and terminally differentiated myotubes is virtually abrogated by TNFα (not shown), this change being only partially prevented by PD administration.

In animal models of PD, administration of D1 or D2 agonists with short half-lives is associated with dyskinetic responses, 54– 57 while exposure to long-acting agonists does not induce dyskinesia.

Furthermore, this agrees with several investigators which reported that Cd and Pd administration increase aminotransferase, especially ALT, as a result of the necrotic lesion in the liver [ 114, 116, 117].

Our model shows some similarities to toxin based models of PD: the administration of MPTP to mice results in dopaminergic neuronal loss mediated by Bax translocation to the mitochondria, cytochrome c release, and activation of caspase 9 and caspase 3.

Our findings suggest that besides PD-1 blockade, anti-PD-L1 antibody administration significantly improved survival of CLP mice, and decreased T cell apoptosis and improved monocyte dysfunction, which may contribute to the beneficial effect of PD-L1 blockade.

Our data show that PD-L1 blockade decreased lymphocyte apoptosis in the spleens and thymuses of septic mice in situ, increased lymphocyte number in peripheral blood, spleens and thymuses, indicating that like PD-1 blockade, anti-PD-L1 antibody administration could indeed inhibit T cell apoptosis.

In conclusion, the present study demonstrates that a brain penetrating form of EPO is neuroprotective in PD following IV administration with minimal effects on erythropoiesis.

Dose-normalised AUC for PD 0332991 after administration of 100 225 mg QD demonstrated dose proportionality (Supplementary Figure 1C).

While site-directed injections have revealed much about the basal ganglia regions in which activating group III mGlu receptors could offer symptomatic potential in PD, routes of administration that can target multiple sites simultaneously give a better indication of the likely translation of these findings into therapeutic strategies.